文献速递膀胱癌与上尿路尿路上皮癌

免疫微环境与分化特征预测膀胱癌结局

Immune Contexture and Differentiation Features Predict Outcome in Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2022-02-25

研究对785例Ta-T4b期膀胱癌原发肿瘤组织行多重免疫荧光和免疫组化染色,数字化定量癌细胞与间质区标志物,分析免疫亚群及癌细胞内在特征与无进展生存、无复发生存及一线化疗反应的关系,并构建结合临床风险因素的预测模型。

要点

  • 高PD-1和PD-L1表达在非肌层浸润性肿瘤中独立关联复发和进展风险增加,在肌层浸润性肿瘤中关联复发风险降低。
  • 具有基底分化特征的患者一线化疗反应可能性较低。
  • 结合临床风险因素与最显著预后标志物的模型,较单用临床风险因素提高了非肌层浸润性膀胱癌进展和肌层浸润性膀胱癌复发的预测准确性。

核心结论

  • 免疫细胞亚群和癌细胞内在特征与膀胱癌不同临床结局相关。

研究设计与样本

  • 研究纳入785例Ta-T4b期膀胱癌患者的原发肿瘤组织,采用多重免疫荧光(CD3、CD8、FOXP3、CD20、CD68、CD163和MHC-I)和免疫组化(泛角蛋白、CK5/6、GATA3、程序性死亡受体1[PD-1]和程序性死亡配体1[PD-L1])染色。
  • 使用数字图像分析定量癌细胞区和肿瘤间质区的染色结果。
  • 主要终点为无进展生存、无复发生存和一线化疗反应。
  • 采用最大选择秩统计量和受试者工作特征曲线估计各主要终点标志物的最佳截断值,采用Cox回归进行时间-事件分析。

主要发现

  • 多个免疫亚群独立关联临床结局。
  • 高PD-1和PD-L1表达在非肌层浸润性肿瘤中独立关联复发和进展风险增加,但在肌层浸润性肿瘤中关联复发风险降低。
  • 具有基底分化特征的患者一线化疗反应可能性较低。
  • 结合临床风险因素与最显著预后标志物的模型,较单用临床风险因素提高了非肌层浸润性膀胱癌进展和肌层浸润性膀胱癌复发的预测准确性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究使用组织微阵列。
  • 纳入时间跨度长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An improved risk assessment of patients with bladder cancer (BC) is important to optimize clinical management. OBJECTIVE: To identify whether immune cell subpopulations and cancer cell-intrinsic features are associated with outcome and response to first-line chemotherapy in BC. DESIGN, SETTING, AND PARTICIPANTS: Primary tumor tissue from 785 patients with BC (stage Ta-T4b) were stained using multiplex immunofluorescence (CD3, CD8, FOXP3, CD20, CD68, CD163, and MHC-I) and immunohistochemistry (pancytokeratin, CK5/6, GATA3, programmed death 1 [PD-1], and programmed death ligand 1 [PD-L1]). A digital image analysis quantified staining results within the carcinoma cell and stromal part of the tumor. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary endpoints were progression-free survival, recurrence-free survival, and response to first-line chemotherapy. Optimal cutoff values for investigated markers were estimated using maximally selected rank statistics and receiver operating characteristic for each primary endpoint. Time-to-event analyses were performed using Cox regression analyses. RESULTS AND LIMITATIONS: Several immune subpopulations were independently associated with clinical outcomes. Especially, high PD-1 and PD-L1 expression was independently associated with an increased risk of recurrence and progression in non-muscle-invasive tumors, but with a lower risk of recurrence in muscle-invasive tumors. Furthermore, we observed a lower likelihood of response to first-line chemotherapy in patients with basal differentiation features. Finally, a model combining clinical risk factors with our most evident prognosticator improved prediction accuracy compared with clinical risk factors alone for progression in non-muscle-invasive BC and recurrence in muscle-invasive BC. The use of tissue microarrays and a long inclusion period are limitations to this study. CONCLUSIONS: Immune cell subpopulations and cancer cell-intrinsic features are associated with different clinical outcomes in BC. PATIENT SUMMARY: Immune cells play an important role in cancer development and treatment outcomes. Infiltration with specific immune cells and the presence of markers associated with immune evasion in the tumor predict clinical outcomes in bladder cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Taber A, Prip F, Lamy P, et al. Immune Contexture and Differentiation Features Predict Outcome in Bladder Cancer. Eur Urol Oncol. 2022. PMID: 35227680. doi:10.1016/j.euo.2022.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。